PHARM - PHARM STOCK NEWS

Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced it will release its preliminary (unaudited) fourth quarter and full year 2024 financial results on Thursday, March 13, 2025. The company will host an analyst and investor presentation at 13:30 CET/08:30 am EDT on the same day.

The presentation will include a conference call for which participants must register in advance to receive dial-in information and a unique PIN. Questions will only be taken from dial-in attendees. A live webcast of the presentation will also be available through advance registration.

Pharming Technologies B.V. has increased its ownership in Abliva AB to 92.70% following its recommended cash offer of SEK 0.45 per share announced on December 15, 2024. During the initial acceptance period ending February 7, 2025, shareholders representing 87.71% of Abliva's shares accepted the offer. An additional 2.94% of shares were tendered during the extended acceptance period, and Pharming acquired 2.05% of shares outside the offer.

The company has further extended the acceptance period until March 6, 2025, to allow remaining shareholders to participate. Settlement for shares tendered during this extended period is expected around March 12, 2025. Pharming plans to initiate a compulsory acquisition procedure for remaining shares and will pursue delisting Abliva from Nasdaq Stockholm.

Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a presentation by CEO Sijmen de Vries and CMO Anurag Relan on Wednesday, February 12 at 08:40 ET/14:40 CET.

Investors can access both the live webcast and replay of the presentation through the 'Upcoming Events' and 'News' sections of Pharming's website. Those interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their Oppenheimer representative.

Pharming Technologies B.V. has successfully completed its recommended cash offer to Abliva AB shareholders, achieving 87.7% acceptance of total shares at SEK 0.45 per share. Although the original offer was conditional upon reaching 90% ownership, Pharming has waived this condition and declared the offer unconditional.

Settlement for shares tendered up to February 7, 2025, is expected around February 14, 2025. The acceptance period has been extended to February 20, 2025, at 15:00 CET, with settlement for this extended period expected around February 27, 2025.

Additionally, Pharming has acquired all outstanding warrants from holders at prices ranging between SEK 0.03-0.054 per warrant. If Pharming reaches 90% ownership, it plans to initiate a compulsory acquisition of remaining shares and pursue delisting from Nasdaq Stockholm.

Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) has announced an Extraordinary General Meeting (EGM) scheduled for March 4, 2025, at 14:00 CET. The primary purpose is to appoint Fabrice Chouraqui as Executive Director and Chief Executive Officer for a four-year term, succeeding Sijmen de Vries. The agenda includes approving components of Chouraqui's remuneration package.

The meeting will be held physically at the Corpus Congress Centre in Oegstgeest, Netherlands, with shareholders having the option to attend in person or follow via live webcast. All relevant documents, including the Notice to Convene, Explanatory Notes, and voting information, are available on the company's website under the Investors/Shareholder Meetings section.

Pharming Group has nominated Fabrice Chouraqui as its new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. The appointment will be for a four-year term, subject to shareholder approval at an upcoming Extraordinary General Meeting. De Vries will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.

Chouraqui brings extensive global pharmaceutical and biotechnology experience. He previously served as CEO-Partner at Flagship Pioneering and CEO of Cellarity, Inc., where he raised over $250M. His prior roles include President of Novartis Pharmaceuticals USA (2016-2019) and various leadership positions at Bristol-Myers Squibb. He holds an MBA from INSEAD and a Doctorate in Pharmacy from the University of Paris V.

Pharming Group N.V. has announced a public cash offer to acquire all shares of Abliva AB for SEK 0.45 per share, valuing the transaction at approximately US$66.1 million. Abliva's lead product, KL1333, is currently in a pivotal clinical trial for treating primary mitochondrial disease (PMD) with mitochondrial DNA mutations, targeting over 30,000 potential patients in the U.S., EU4, and UK.

The acquisition will be funded through existing cash, with Abliva's Board of Directors unanimously recommending shareholders accept the offer. The company has secured acceptance undertakings from the three largest shareholders, representing 49.82% of outstanding shares. The acceptance period is expected to run from January 16, 2025, to February 7, 2025.

Pharming Group announces positive topline results from its Phase III clinical trial of leniolisib in children aged 4-11 years with APDS (activated phosphoinositide 3-kinase delta syndrome), a rare primary immunodeficiency. The trial enrolled 21 children across the US, Europe, and Japan, evaluating the oral PI3Kδ inhibitor's safety, tolerability, and efficacy.

The study met its primary endpoints, showing improvement in lymphoproliferation and immunophenotype correction across all dose levels, consistent with previous results in adolescent and adult patients. All patients completed the 12-week treatment period with only mild to moderate adverse events reported. Pharming plans to include this data in global regulatory filings for pediatric approval starting in 2025.

Pharming Group has announced its participation in the Jefferies London Healthcare Conference 2024, scheduled for November 19-21 in London, U.K. CEO Sijmen de Vries will deliver a presentation on Wednesday, November 20 at 08:00 GMT/09:00 CET. The presentation will be accessible via live webcast, with a replay available in the 'Upcoming Events' and 'News' sections of Pharming's website. Interested parties can arrange one-to-one meetings with Pharming's management team by contacting their Investor Relations team or Jefferies representative.